Evidence map›Paper›PMID 40324865›Full record

SynthesisFuture cardiology2025

Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.

Noman Khalid, Muhammad Adil Afzal, Muhammad Abdullah, Ata-Ul Haiy, Yezin Shamoon, Sherif Elkattawy, Muhammad Aamir Laghari, Rahul Vasudev, Shamoon E Fayez, Yasotha Rajeswaran and 2 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Noman KhalidDepartment of Internal Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA.
Muhammad Adil AfzalDepartment of Internal Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA.
Muhammad AbdullahDepartment of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Pakistan.
Ata-Ul HaiyDepartment of Internal Medicine, UHS Wilson Medical Center, Johnson City, NY, USA.
Yezin ShamoonDepartment of Cardiology, St. Joseph's University Medical Center, Paterson, NJ, USA.
Sherif ElkattawyDepartment of Cardiology, St. Joseph's University Medical Center, Paterson, NJ, USA.
Muhammad Aamir LaghariDepartment of Cardiology, Lehigh Valley Health Network, Allentown, PA, USA.
Rahul VasudevDepartment of Cardiology, St. Joseph's University Medical Center, Paterson, NJ, USA.
Shamoon E FayezDepartment of Cardiology, St. Joseph's University Medical Center, Paterson, NJ, USA.
Yasotha RajeswaranDepartment of Cardiology, Lehigh Valley Health Network, Allentown, PA, USA.
Gregg M LanierDivision of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Wilbert AronowDivision of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute heart failure (AHF) is leading cause of hospitalization and mortality. Empagliflozin, a Sodium Glucose Co-transporter 2 inhibitor (SGLT-2i), has demonstrated benefits in HFrEF and HFpEF, but its role in AHF remains under-explored.

objectiveAssess safety and efficacy of empagliflozin in AHF.

methodsA systematic review and meta-analysis adhering to PRISMA 2020 guidelines was conducted. A search on 25 February 2025, identified Phase IIb and III randomized controlled trials (RCTs) involving adults with AHF from databases like Medline®, Cochrane CENTRAL, Embase, and ClinicalTrials.gov. Outcomes included all-cause mortality, HF rehospitalization, cardiovascular deaths, and serious adverse events. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed with I2 and Cochrane Q-statistic.

resultsThree RCTs (

conclusionEmpagliflozin reduces mortality in AHF with a favorable safety profile, highlighting need for further trials.

Indexed as

Benzhydryl CompoundsGlucosidesHeart FailureSodium-Glucose Transporter 2 InhibitorsAcute DiseaseHumansTreatment OutcomeBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsacute heart failureEmpagliflozinheart failureSGLT2isodium glucose co-transporter 2 inhibitor

Identifiers

PMID40324865
PMCPMC12506710

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.